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Abstract  
Objectives: Mammography screening seems not to play a major role in breast cancer 
mortality reductions observed in many populations. However the overview of Swedish trials 
of 2002 reported relative risks of 0.79 (95% CI: 0.70; 0.89) for the risk of breast cancer death 
associated with mammography screening. We compared investigated how calculations of 
relative risks of cancer death made in Swedish mammography trials and compared to 
calculation in other cancer screening trials.  
Setting: Randomized trials on cancer screening. 
Design: For each trial, Within the follow-up period of each trial, we identified the 
intervention period, when screening was offered to screening groups and not to control 
groups, and the post-intervention period, when screening (or absence of screening) was the 
same in screening and control groups. We then examined which cancer deaths had been 
used for the computation of relative risk of cancer death. 
Main outcome measures: Relative risk of cancer death. 
Results: In 17 non-breast screening trials, deaths due to cancer diagnosed during the follow-
up periods were used for relative risk calculations. In the 5 Swedish trials, relative risk 
calculations used deaths due to breast cancers found during intervention periods, but deaths 
due to breast cancer found at first screening of control groups were added to these groups. 
After re-allocation of the added breast cancer deaths to post-intervention periods of control 
groups, relative risks of 0.86 (0.76; 0.97) were obtained for cancers found during 
intervention periods and 0.83 (0.71; 0.97) for cancers found during post intervention 
periods, indicating constant reduction in the risk of breast cancer death during follow-up, 
irrespective of screening. 
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Conclusions: The use of unconventional statistical methods in Swedish trials has led to over-
estimation of risk reduction in breast cancer death attributable to mammography screening. 
The constant risk reduction observed in screening groups was probably due to the trial 
design that optimized awareness and medical management of women allocated to screening 
groups compared to women allocated to control groups. 
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Introduction 
Between 1977 and 1996, five randomized trials on mammography screening were 
conducted in Sweden, including women aged 40-74 at trial start. An overview of these trials 
published in 2002 reported that that 2 to 4 rounds of mammography screening could 
decrease breast cancer risk by 21 % (relative risk of 0.79; 95% CI: 0.70; 0.89)(1). This meta-
analysis is considered the strongest evidence proving the efficacy of periodic mammography 
screening 2.  
Mammography screening works through finding non-clinically detectable breast cancer 
before progression into advanced cancer with metastatic spread in lymph nodes and distant 
organs. Since reduction in cancer deaths due to reduction in the incidence of advanced 
cancer is not influenced by treatment efficacy, it was concluded from Swedish trials that 
decreases in the incidence of advanced breast cancer after screening introduction would 
provide the best indication that mammography screening reduces breast cancer mortality 
(2).  
However, in communities where screening participation was high for more than ten years, 
only modest or no declines in the incidence of advanced breast cancer were observed (3-12). 
This e situation of breast cancer screening is in sharp contrast with that of colorectal and 
cervical cancer screening because in communities where screening for cervical and 
colorectal cancers is widespread, marked declines in the incidence of these types of cancers 
at an advanced stage have been observed, which indicates a substantial contribution of 
these screening modalities (13, 14) because  
. Randomized trials have shown that screening for the latter two cancers reduced the risk of 
advanced cancer and of cancer death 16 17. Iin communities where screening for cervical and 
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colorectal cancers is widespread, marked declines in the incidence of these types of cancers 
at an advanced stage have been observed, which indicates a substantial contribution of 
these screening modalities (13, 14).  
Breast screening trials were initiated at a time (1980’s) when there was limited experience 
for designing, conducting and analyzing cancer screening trials (15). We therefore postulate 
that the contrasts between breast and cervical or colorectal cancers could be due to 
differences in the way randomized trials were conducted and analyzed. In this study, we re-
examine the mortality data used and the way risks of breast cancer death were computed in 
Swedish trials in the light of study design and statistical analyses performed in screening 
trials on cancers other than breast cancer.  
Designs of randomized trials for the evaluation of cancer screening tests 
These trials are typically composed of two successive periods (Figure 1a): the intervention 
period that extends from randomization to termination of the last screening round in the 
screening group, and the post-intervention period that extends from the end of the last 
screening round in the screening group to the date of last check of vital status of subjects 
that were included in the trial. The follow-up period is the total of the intervention and the 
post-intervention periods. Depending on the number of screening rounds and follow-up 
extent, intervention and post-intervention periods may be of variable duration. Randomized 
trials evaluating cancer screening methods may consist of a single intervention of short 
duration including invitation to screening, the screening test itself and possible work up 
procedures in case of suspicious screening result. In other trials, the intervention period lasts 
for several years because the screening test is repeated every year or every two years. After 
the last screening round in the screening group, screening may be interrupted. Alternatively, 
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screening may be pursued in the screening group and implemented in the control group, 
when for instance, decision is taken to launch a population screening program. 
Relative risks of cancer death associated with screening are computed by dividing the cancer 
death rate in the screening group by the cancer death rate in the control group (Box). Cancer 
death rates can be calculated using deaths due to cancers found during the follow-up period 
as numerator (follow-up method), or using deaths due to cancers found during the 
intervention period as numerator (evaluation method). Denominators are the same in both 
methods. If in a trial, there is no post-intervention period, then the evaluation and follow-up 
periods coincides. During post-intervention periods, because screening (or absence of 
screening) activities are similar in the screening and in the control group, cancer detection 
rates in the two groups (i.e., Dsp/Ns and Dcp/Nc in Box) are also similar. In the follow-up 
method, growing numbers of deaths due to cancers found during steadily longer post-
intervention periods will progressively narrow (or dilute) the difference in cancer death rates 
between the two groups.  In this regard, reduction in the risk of cancer death calculated 
according to the follow-up method may be smaller than when calculated according to the 
evaluation method. For instance, in the fecal-occult-blood-test (FOBT) trial in England, the 
relative risk of colorectal cancer death after 7.7 years of follow-up (6.7 years of intervention 
and 1 year of post-intervention) was 0.85 (95% CI: 0.74;0.94) and 0.91 (95% CI: 0.84;0.98) 
after 20 years of follow-up (6.7 years of intervention and 13.3 years of post-
intervention)(16)For instance, in the fecal-occult-blood-test (FOBT) trial in England, the 
relative risk of colorectal cancer death after 7.7 years of follow-up (6.7 years of intervention 
and 1 year of post-intervention) was 0.85 (95% CI: 0.74;0.94)20. After 20 years of follow-up 
(6.7 years of intervention and 13.3 years of post-intervention) the relative risk was 0.91 (95% 
CI: 0.84;0.98)19. 
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Cause of death assessment and statistical analysis in trials on screening for cancer other 
than breast cancer 
We retrieved publications on 17 cancer screening trials other than breast cancer in which 
main trial results were presented (see eTable 1 in the Supplement). In 14 trials, cause of 
death assessment was done by committees unaware of the screening status of subjects that 
decided on likely causes of death using all available information. In all 17 trials, the relative 
risk of cancer-specific death associated with screening was calculated using deaths due to 
target cancers found during follow-up periods (follow-up method).  
Cause of death assessment and statistical analysis in breast cancer screening trials 
Committees for cause of death assessment independent of trial conduct and blinded as to 
the screening status of deceased women were implemented in the HIP (17) and in the 
Canadian trials (18-20)(Table 1)(1, 18, 21-23). The Two-County trial used causes of death 
established by local endpoint committees or a Joint Review Committee, both of which 
included trial investigators (24). Swedish trials included in the overview of 2002 and in the 
Age trial used causes of death reported on death certificates (1, 23). 
To avoid dilution of risk reductions caused by breast cancer deaths of cancers found after 
the intervention period, main results in all breast screening trials were based on the 
evaluation method. All Bbreast screening trials conducted in the USA, Canada and England 
calculated relative risks of breast cancer death associated with screening using deaths due to 
breast cancers found during the intervention period of the screening and of the control 
groups (Evaluation method)(Table 1). In contrast, tHowever, the Swedish trials and their he 
overview of Swedish trials used a different selection of breast cancer deaths for control 
goups, as one sentence in the statistical section of the 2002 overview makes clear, “The 
evaluation [method] ignores breast cancer deaths among women whose breast cancer 
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diagnosis was made after the first screening round of the control group was completed”(1). 
This means that the breast cancer deaths in the control group that were used for calculating 
the relative risk included breast cancer deaths related to cancer cases found at first 
screening of this group (RC1 in Figure 1b). In the Two-County, Malmö and in the Stockholm 
trials, tThis first screening of the control group generally took place in years following the 
last screening round in the screening group (25-27). In the Goteborg trial, about half of first 
screening was done at the time of the last screening round of the screening group, and 
about half was done 3 to 8 months after the last screening round (28). Hence, most breast 
cancers found at first screening of the control group were in fact part of the post-
intervention period, and if screening of the control group had not taken place, these cancers 
would have been diagnosed during the post-intervention period. Thus, this incorporation 
approach was thus equivalent to transferring to the intervention period a number of cancers 
and associated deaths that were part of the post-intervention period. It is important to note 
that this approach was applied to the control group only. As a consequence, publications 
reported more cancers per women in control groups than per women in screening groups 
(28-30). Translating this incorporation approach in equations displayed in Box gives:  
RREM/ST = (DSI/NS)/[(DCI + DRC1)/NC], where RREM/ST stands for the evaluation method specific 
to Swedish trials. DRC1 are deaths due to breast cancers found at first screening of the control 
group that pertain to the post-intervention period, (i.e., DCP in Box) and not to the 
intervention period, (i.e., DCI in Box)  
The Two-County and the Stockholm trials reported numbers and stage of cancers found at 
first screening of control groups, showing that the incorporation approach resulted in adding 
72 advanced (i.e., 20 mm size or more) cancers to the 434 advanced cancers diagnosed in 
the control group during the intervention period of the Two-County trial(25) and 30 
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advanced cancers (i.e., stage 2 or more) to the 173 advanced cancers diagnosed in the 
control group during the intervention period of the Stockholm trial(31). Because of their high 
fatality rate, these extra advanced cancers led to a substantial number of extra cancer 
deaths i.e., DRC1. Thus the greater the value of DRC1, the smaller the value of RREM/ST and thus 
the greater the apparent reduction in the risk of breast cancer death associated with 
mammography screening.    
Alternative calculation of results of Swedish trials 
We estimated a relative risk according to the evaluation method that would not incorporate 
deaths due to cancers found at first screening of control groups, that is, we estimated DCI 
and DRC1 of the RREM/ST equation. In Swedish trials, the ratio between breast cancer mortality 
rates in the screening and control groups remained relatively equivalent after 10 to 12 years 
of follow-up (1, 22). Furthermore, the Two-County trial reported that after 29 years of 
follow-up, 10% of breast cancer deaths in the control group were associated with cancers 
found during the first screening of control women (22). The 10% figure is plausible because 
follow-up of the additional cancers was shorter than for cancers found during intervention 
periods. We thus inferred that 10% represented a valid estimate of the proportion of extra 
deaths added to intervention periods of control groups in the overview of 2002. 
Table 2 displays the main results of the overview of 2002 1.  
The evaluation method specific to Swedish trials found a relative risk of 0.79 while the 
follow-up method found a relative risk of 0.85, reflecting dilution of effect over time (Table 
2). Reduction of the risk of breast cancer death is smaller with the follow-up method 
because of the dilution by the addition of breast cancer deaths related to breast cancers 
found during the post-intervention period, when screening activities in both groups were 
identical. 
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Trial-specific data on breast cancer deaths are displayed in Table 3.  
In the central column of this tTable 3, we estimated breast cancer deaths linked to cases 
found at first screening of control women by multiplying by 10% the number of breast 
cancer deaths in control groups of the Östergötland, Goteborg, and Stockholm trials. The 
10% hypothesis was probably excessive for the Malmö I trial because first screening of 
control group concerned women born in 1923-32, and not women born in 1908-2236, i.e., 
about 45% of the total number of control women included in the trial37. We thus set the 
estimate to 4.5% for Malmö I because first screening of control group concerned about 45% 
of the total number of control women included in the trial(32). In Malmö II, we set estimates 
to 7.5% because the follow-up period lasted 9.1 years(1), i.e., about three-quarter of 12 
years. Therefore, we set estimates to 7.5% for Malmö II. We obtained an estimate of 46 
breast cancer deaths related to breast cancers found at first screening of control groups. In 
the two right-hand columns, we re-allocated to post-intervention periods the 46 breast 
cancer deaths associated with cases found during first screening of control groups.  
We then re-worked results of the overview of 2002 (1) in Table 2 using numbers of breast 
cancer deaths in control groups we estimated in Table 3. The relative risk of breast cancer 
death over the follow-up period remained unchanged, but the relative risk of breast cancer 
death for the evaluation method was 0.86 instead of 0.79. For breast cancers diagnosed 
during the post-intervention period, the relative risk of breast cancer death dropped to 0.83. 
Sensitivity analysis using 8 or 12% for re-working numbers of breast cancer deaths in control 
groups of the Östergötland, Goteborg, and Stockholm trials did not change much the 
corrected relative risk estimates (data not shown). 
So, proper allocation of breast cancer deaths to the intervention and post-intervention 
periods led to an equalization of relative risks found for the intervention, post-intervention, 
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and follow-up periods, with a risk of breast cancer death that remained about 15% lower in 
the screening group throughout the entire trial duration.  
Discussion  
Computations performed  by the overview of Swedish mammography trials incorporated 
deaths of breast cancers found at first screening of the control group as if these cancers 
were part of intervention periods (1). The consequence of this incorporation approach was 
the overestimation of rates of breast cancer death in the control groups, which ended up in 
the overestimation of the protection conferred by mammography screening against breast 
cancer death. Other authors raised similar concerns, estimating that the evaluation method 
adopted by Swedish trials resulted in including in the control groups many cancers that 
would not have been found in the screening group, which biased results in favor of screening 
(33). 
Non-Swedish breast screening trials and trials on screening for cancer other than breast 
cancer never used the incorporation approach and . In contrast, whenever possible, Swedish 
trials had recourse to the incorporation approach. But we found practically no 
methodological justification for this approach. The second publication on Swedish trials 
overview just provided an ethical justification 39. The 2002 overview 1 did not comment on 
the incorporation approach. The Goteborg trial investigators argued that there was a need 
to compensate for the extra number of cancer found by screening that are included for 
follow-up to death in the screening group (28, 34). However all extra screen-detected 
invasive cancers in screening groups were early cancers, i.e., tumors less than 20 mm 
diameter or stage 1 (25, 29, 31, 32). Hence, the conceivable need to compensate for screen 
detection of extra numbers of early cancer could not justify the transfer to intervention 
periods of substantial numbers of advanced cancers found at first screening of control 
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groups. Substantial numbers of extra cancers were also found in screening groups of trials of 
prostate and lung cancer. However, none of these trials resorted to screening the control 
group after termination of the intervention and to transfer these cancers to the intervention 
period. The compensation argument invoked by Swedish trial investigators (28, 34) is thus 
not tenable. 
Our re-calculations of Swedish trial revealed that risks of breast cancer death were similar 
for cancers found during the intervention and the post-intervention periods, indicating that 
reductions in the risk of breast cancer death also applied to cancer cases diagnosed when 
screening (or absence of screening) was the same in both screening and control groups. Such 
result is compatible with an effect of being allocated to the screening or to the control group 
on the risk of breast cancer death (allocation effect), but not with an effect of 
mammography screening (screening effect) on that risk.  
Two reasons could explain a lower risk of breast cancer deaths independent of 
mammography screening. First, the HIP (21), Age (23)and all Swedish trials (1, 22, 28, 30, 32, 
35) that found decreased risk of breast cancer death associated with mammography 
screening adopted a “left-to-nature” design. Typically, parallel group randomized trials first 
recruit a group of eligible subjects that are informed on trial objectives, on potential health 
benefits and probable side effects. Subjects agreeing to participate must first sign an 
informed consent form after which they are randomized in an intervention or in a control 
group. In left-to-nature trials, only women invited to participate in breast screening knew 
they were part of a clinical trial. Women allocated to control groups were never contacted, 
did not sign an informed consent and were completely ignorant they were part of a trial. 
Health professionals knew or could detect which women were invited to screening but did 
not know which women were allocated to control groups. Imbalance between the two 
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groups probably led to increased awareness and better information (e.g., on early breast 
symptoms) and medical management of women in screening groups. Women invited to 
screening had probably quicker access to specialized care than women in control groups. 
The Two-County trial provides the best evidence for factors other than mammography 
screening influencing breast cancer mortality. Besides mammography screening, the 
intervention also encompassed enhancing breast cancer awareness, breast self-examination, 
and rapid referral of women presenting at screening with breast symptoms, all factors that 
would have, according to investigators, reduced patient delay and led to earlier detection of 
interval cancers and their treatment (36). In addition, the Two-County trial randomized 
women by geographical cluster, each cluster comprising about 2,700 women in Dalarna 
(Kopparberg) county and about 3,200 women in Östergötland county (25, 37). This large 
cluster randomization scheme is likely to have exacerbated differences between screening 
and control groups with respect to information, awareness and medical management. 
Finally, some data indicate different management of breast cancer patients according to 
randomization group: the histological grade of cancers found during the Two-County trial 
was unknown for 19% of patients in the control group vs. 10% in the screening group 
(p<0.0001)(25). Lymph node status was missing for 5.0% of patients in the screening group 
and 7.3% of patients in the control group (p=0.0396)(25).  
It seems likely that Swedish mammography screening trials have departed from the “ceteris 
paribus” principle by which an experiment evaluating the effect of one action must make 
sure that all other things remain equal and will not interfere with study results. 
In contrast, the Canadian trials that found no reduction in the risk of breast cancer death 
associated with mammography screening, adopted the typical parallel group randomized 
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trial design. All enrolled women were volunteers who signed an informed consent form 
before randomization and received the same information and medical attention (18-20).  
A second reason for the persistent lower risk of breast cancer death for cancers found in the 
intervention and post-intervention periods could be biased attribution of causes of death. Of 
the 8 major breast screening trials, only the HIP and the Canadian trial implemented 
endpoint committees unaware of the screening status of deceased women. In left-to-nature 
trials, health professionals completing death certificates of being part of local endpoint 
committees may have known or guessed which women have been invited to screening but 
had no idea regarding women allocated to control groups. To circumvent this problem, the 
overview of 2002 used death certificates for cause of death assessment because the 
overview of 1993 found that causes reported on certificates correlated well with causes 
established by an independent endpoint committee that had access to all medical and 
necropsy information(1, 38). However, in the 2002 overview, there were nearly twice as 
many breast cancer deaths for the Malmö, Östergötland, Stockholm and Goteborg trials than 
in the 1993 overview (39) and it is unknown up to which point the reliability of death 
certificates was maintained over time. 
In conclusion, unconventional computation of the relative risk of breast cancer death 
impacted on the reported results of the Swedish trials on mammography screening. This led 
to an intrinsic bias in favor of screening. If calculations of relative risks had been carried out 
using similar methodological approaches to other cancer screening trials conducted in the 
more recent era, the Swedish trials would not have found a 20% reduction of breast cancer 
death due to mammography screening. This conclusion can be verified through a re-analysis 
of Swedish trial original data according to methods used in other cancer screening trials.  
Supplementary materials: 	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CAPTIONS 
 
Figure 1 – Design of randomized trials for the evaluation of cancer screening methods  
(R : screening round). Intervention periods are the continuous lines and the post-
intervention periods are the dashed lines. (a) Typical design; (b) design specific to Swedish 
trials on breast cancer screening. 
 
Box – Computation of relative risk (RR) of cancer death in randomized trials on cancer 
screening 
 
Table 1 - Data used for relative risks calculation in randomized trials on breast cancer 
screening 
Table 2 - Breast cancer deaths in the Swedish trials included in the 2002 overview 
Table 3 - Breast cancer deaths in Swedish mammography trials 
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Abstract  
Objectives: We compared calculations of relative risks of cancer death in Swedish 
mammography trials and in other cancer screening trials.  
Setting: Randomized trials on cancer screening. 
Design: For each trial, we identified the intervention period, when screening was offered to 
screening groups and not to control groups, and the post-intervention period, when 
screening (or absence of screening) was the same in screening and control groups. We then 
examined which cancer deaths had been used for the computation of relative risk of cancer 
death. 
Main outcome measures: Relative risk of cancer death. 
Results: In 17 non-breast screening trials, deaths due to cancers diagnosed during the 
follow-up periods were used for relative risk calculations. In the 5 Swedish trials, relative risk 
calculations used deaths due to breast cancers found during intervention periods, but deaths 
due to breast cancer found at first screening of control groups were added to these groups. 
After re-allocation of the added breast cancer deaths to post-intervention periods of control 
groups, relative risks of 0.86 (0.76; 0.97) were obtained for cancers found during 
intervention periods and 0.83 (0.71; 0.97) for cancers found during post intervention 
periods, indicating constant reduction in the risk of breast cancer death during follow-up, 
irrespective of screening. 
Conclusions: The use of unconventional statistical methods in Swedish trials has led to over-
estimation of risk reduction in breast cancer death attributable to mammography screening. 
The constant risk reduction observed in screening groups was probably due to the trial 
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design that optimized awareness and medical management of women allocated to screening 
groups. 
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Introduction 
Between 1977 and 1996, five randomized trials on mammography screening were 
conducted in Sweden. An overview of these trials published in 2002 reported that that 2 to 4 
rounds of mammography screening could decrease breast cancer risk by 21 % (1).  
Mammography screening works through finding non-clinically detectable breast cancer 
before progression into advanced cancer with metastatic spread in lymph nodes and distant 
organs. Since reduction in cancer deaths due to reduction in the incidence of advanced 
cancer is not influenced by treatment efficacy, it was concluded from Swedish trials that 
decreases in the incidence of advanced breast cancer after screening introduction would 
provide the best indication that mammography screening reduces breast cancer mortality 
(2).  
However, in communities where screening participation was high for more than ten years, 
only modest or no declines in the incidence of advanced breast cancer were observed (3-5). 
This situation is in sharp contrast with that of colorectal and cervical cancer screening, 
because in communities where screening for cervical and colorectal cancers is widespread, 
marked declines in the incidence of these types of cancers at an advanced stage have been 
observed, which indicates a substantial contribution of these screening modalities (6, 7).  
Breast screening trials were initiated at a time when there was limited experience for 
designing, conducting and analyzing cancer screening trials. We therefore postulate that the 
contrasts between breast and cervical or colorectal cancers could be due to differences in 
the way randomized trials were conducted and analyzed. In this study, we re-examine the 
mortality data used and the way risks of breast cancer death were computed in Swedish 
trials in the light of study design and statistical analyses performed in screening trials on 
cancers other than breast cancer.  
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Designs of randomized trials for the evaluation of cancer screening tests 
These trials are typically composed of two successive periods (Figure 1a): the intervention 
period that extends from randomization to termination of the last screening round in the 
screening group, and the post-intervention period that extends from the end of the last 
screening round in the screening group to the date of last check of vital status of subjects 
that were included in the trial. The follow-up period is the total of the intervention and the 
post-intervention periods. Depending on the number of screening rounds and follow-up 
extent, intervention and post-intervention periods may be of variable duration. Randomized 
trials evaluating cancer screening methods may consist of a single intervention of short 
duration including invitation to screening, the screening test itself and possible work up 
procedures in case of suspicious screening result. In other trials, the intervention period lasts 
for several years because the screening test is repeated every year or every two years. After 
the last screening round in the screening group, screening may be interrupted. Alternatively, 
screening may be pursued in the screening group and implemented in the control group, 
when for instance, decision is taken to launch a population screening program. 
Relative risks of cancer death associated with screening are computed by dividing the cancer 
death rate in the screening group by the cancer death rate in the control group (Box). Cancer 
death rates can be calculated using deaths due to cancers found during the follow-up period 
as numerator (follow-up method), or using deaths due to cancers found during the 
intervention period as numerator (evaluation method). Denominators are the same in both 
methods. If in a trial, there is no post-intervention period, then the evaluation and follow-up 
periods coincides. During post-intervention periods, because screening (or absence of 
screening) activities are similar in the screening and in the control group, cancer detection 
rates in the two groups (i.e., Dsp/Ns and Dcp/Nc in Box) are also similar. In the follow-up 
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method, growing numbers of deaths due to cancers found during steadily longer post-
intervention periods will progressively narrow (or dilute) the difference in cancer death rates 
between the two groups.  In this regard, reduction in the risk of cancer death calculated 
according to the follow-up method may be smaller than when calculated according to the 
evaluation method. For instance, in the fecal-occult-blood-test (FOBT) trial in England, the 
relative risk of colorectal cancer death after 7.7 years of follow-up (6.7 years of intervention 
and 1 year of post-intervention) was 0.85 (95% CI: 0.74;0.94) and 0.91 (95% CI: 0.84;0.98) 
after 20 years of follow-up (6.7 years of intervention and 13.3 years of post-intervention)(8). 
Cause of death assessment and statistical analysis in trials on screening for cancer other 
than breast cancer 
We retrieved publications on 17 cancer screening trials other than breast cancer in which 
main trial results were presented (see eTable in the Supplement). In 14 trials, cause of death 
assessment was done by committees unaware of the screening status of subjects that 
decided on likely causes of death using all available information. In all 17 trials, the relative 
risk of cancer-specific death associated with screening was calculated using deaths due to 
target cancers found during follow-up periods (follow-up method).  
Cause of death assessment and statistical analysis in breast cancer screening trials 
Committees for cause of death assessment independent of trial conduct and blinded as to 
the screening status of deceased women were implemented in the HIP (9) and in the 
Canadian trials (10)(Table 1). The Two-County trial used causes of death established by local 
endpoint committees or a Joint Review Committee, both of which included trial investigators 
(11). Swedish trials included in the overview of 2002 and in the Age trial used causes of 
death reported on death certificates (1, 12). 
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All breast screening trials calculated relative risks of breast cancer death associated with 
screening using deaths due to breast cancers found during the intervention period of the 
screening and of the control groups (Evaluation method)(Table 1). However, the Swedish 
trials and their overview used a different selection of breast cancer deaths for control 
groups, as one sentence in the statistical section of the 2002 overview makes clear, “The 
evaluation [method] ignores breast cancer deaths among women whose breast cancer 
diagnosis was made after the first screening round of the control group was completed”(1). 
This means that the breast cancer deaths in the control group that were used for calculating 
the relative risk included breast cancer deaths related to cancer cases found at first 
screening of this group (RC1 in Figure 1b). This first screening of the control group generally 
took place in years following the last screening round in the screening group (13-16). Hence, 
if screening of the control group had not taken place, these cancers would have been 
diagnosed during the post-intervention period. This incorporation approach was thus 
equivalent to transferring to the intervention period a number of cancers and associated 
deaths that were part of the post-intervention period. It is important to note that this 
approach was applied to the control group only. As a consequence, publications reported 
more cancers per women in control groups than per women in screening groups (16-18). 
Translating this incorporation approach in equations displayed in Box gives:  
RREM/ST = (DSI/NS)/[(DCI + DRC1)/NC], where RREM/ST stands for the evaluation method specific 
to Swedish trials. DRC1 are deaths due to breast cancers found at first screening of the control 
group that pertain to the post-intervention period, (i.e., DCP in Box) and not to the 
intervention period, (i.e., DCI in Box)  
The Two-County and the Stockholm trials reported numbers and stage of cancers found at 
first screening of control groups, showing that the incorporation approach resulted in adding 
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72 advanced (i.e., 20 mm size or more) cancers to the 434 advanced cancers diagnosed in 
the control group during the intervention period of the Two-County trial (13) and 30 
advanced cancers (i.e., stage 2 or more) to the 173 advanced cancers diagnosed in the 
control group during the intervention period of the Stockholm trial (19). Because of their 
high fatality rate, these extra advanced cancers led to a substantial number of extra cancer 
deaths i.e., DRC1. Thus the greater the value of DRC1, the smaller the value of RREM/ST and thus 
the greater the apparent reduction in the risk of breast cancer death associated with 
mammography screening. 
Alternative calculation of results of Swedish trials 
We estimated a relative risk according to the evaluation method that would not incorporate 
deaths due to cancers found at first screening of control groups, that is, we estimated DCI 
and DRC1 of the RREM/ST equation. In Swedish trials, the ratio between breast cancer mortality 
rates in the screening and control groups remained relatively equivalent after 10 to 12 years 
of follow-up (1, 20). Furthermore, the Two-County trial reported that after 29 years of 
follow-up, 10% of breast cancer deaths in the control group were associated with cancers 
found during the first screening of control women (20). The 10% figure is plausible because 
follow-up of the additional cancers was shorter than for cancers found during intervention 
periods. We thus inferred that 10% represented a valid estimate of the proportion of extra 
deaths added to intervention periods of control groups in the overview of 2002. 
The evaluation method specific to Swedish trials found a relative risk of 0.79 while the 
follow-up method found a relative risk of 0.85, reflecting dilution of effect over time (Table 
2).  
In the central column of Table 3, we estimated breast cancer deaths linked to cases found at 
first screening of control women by multiplying by 10% the number of breast cancer deaths 
Page 31 of 51
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Journal of the Royal Society of Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Under Review
10 
 
in control groups of the Östergötland, Goteborg, and Stockholm trials. We set the estimate 
to 4.5% for Malmö I because first screening of control group concerned about 45% of the 
total number of control women included in the trial (21). In Malmö II, we set estimates to 
7.5% because the follow-up period lasted 9.1 years (1) We obtained an estimate of 46 breast 
cancer deaths related to breast cancers found at first screening of control groups. In the two 
right-hand columns, we re-allocated to post-intervention periods the 46 breast cancer 
deaths associated with cases found during first screening of control groups.  
We then re-worked results of the overview of 2002 (22) in Table 2 using numbers of breast 
cancer deaths in control groups we estimated in Table 3. The relative risk of breast cancer 
death over the follow-up period remained unchanged, but the relative risk of breast cancer 
death for the evaluation method was 0.86 instead of 0.79. For breast cancers diagnosed 
during the post-intervention period, the relative risk of breast cancer death dropped to 0.83. 
Sensitivity analysis using 8 or 12% for re-working numbers of breast cancer deaths in control 
groups of the Östergötland, Goteborg, and Stockholm trials did not change much the 
corrected relative risk estimates (data not shown). 
So, proper allocation of breast cancer deaths to the intervention and post-intervention 
periods led to an equalization of relative risks found for the intervention, post-intervention, 
and follow-up periods, with a risk of breast cancer death that remained about 15% lower in 
the screening group throughout the entire trial duration.  
Discussion  
Computations performed by the overview of Swedish mammography trials incorporated 
deaths of breast cancers found at first screening of the control group as if these cancers 
were part of intervention periods (1). The consequence of this incorporation approach was 
the overestimation of rates of breast cancer death in the control groups, which ended up in 
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the overestimation of the protection conferred by mammography screening against breast 
cancer death. Other authors raised similar concerns, estimating that the evaluation method 
adopted by Swedish trials resulted in including in the control groups many cancers that 
would not have been found in the screening group, which biased results in favor of screening 
(23). 
Non-Swedish breast screening trials and trials on screening for cancer other than breast 
cancer never used the incorporation approach and we found practically no methodological 
justification for this approach. The Goteborg trial investigators argued that there was a need 
to compensate for the extra number of cancer found by screening that are included for 
follow-up to death in the screening group (16, 24). However all extra screen-detected 
invasive cancers in screening groups were early cancers, i.e., tumors less than 20 mm 
diameter or stage 1 (13, 17, 19, 25). Hence, the conceivable need to compensate for screen 
detection of extra numbers of early cancer could not justify the transfer to intervention 
periods of substantial numbers of advanced cancers found at first screening of control 
groups. Substantial numbers of extra cancers were also found in screening groups of trials of 
prostate and lung cancer. However, none of these trials resorted to screening the control 
group after termination of the intervention and to transfer these cancers to the intervention 
period. The compensation argument invoked by Swedish trial investigators (16, 24) is thus 
not tenable. 
Our re-calculations of Swedish trial revealed that risks of breast cancer death were similar 
for cancers found during the intervention and the post-intervention periods, indicating that 
reductions in the risk of breast cancer death also applied to cancer cases diagnosed when 
screening (or absence of screening) was the same in both screening and control groups. Such 
result is compatible with an effect of being allocated to the screening or to the control group 
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on the risk of breast cancer death (allocation effect), but not with an effect of 
mammography screening (screening effect) on that risk.  
Two reasons could explain a lower risk of breast cancer deaths independent of 
mammography screening. First, the HIP (26), Age (12) and all Swedish trials (1, 16, 18, 20, 25, 
27) that found decreased risk of breast cancer death associated with mammography 
screening adopted a “left-to-nature” design. Typically, parallel group randomized trials first 
recruit a group of eligible subjects that are informed on trial objectives, on potential health 
benefits and probable side effects. Subjects agreeing to participate must first sign an 
informed consent form after which they are randomized in an intervention or in a control 
group. In left-to-nature trials, only women invited to participate in breast screening knew 
they were part of a clinical trial. Women allocated to control groups were never contacted, 
did not sign an informed consent and were completely ignorant they were part of a trial. 
Health professionals knew or could detect which women were invited to screening but did 
not know which women were allocated to control groups. Imbalance between the two 
groups probably led to increased awareness and better information (e.g., on early breast 
symptoms) and medical management of women in screening groups. Women invited to 
screening had probably quicker access to specialized care than women in control groups. 
The Two-County trial provides the best evidence that factors other than mammography 
screening influenced breast cancer mortality. Besides mammography screening, the 
intervention also encompassed enhancing breast cancer awareness, breast self-examination, 
and rapid referral of women presenting at screening with breast symptoms, all factors that 
would have, according to investigators, reduced patient delay and led to earlier detection of 
interval cancers and their treatment (28). In addition, the Two-County trial randomized 
women by geographical cluster, each cluster comprising about 2,700 women in Dalarna 
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(Kopparberg) county and about 3,200 women in Östergötland county (13). This large cluster 
randomization scheme is likely to have exacerbated differences between screening and 
control groups with respect to information, awareness and medical management. Finally, 
some data indicate different management of breast cancer patients according to 
randomization group: the histological grade of cancers found during the Two-County trial 
was unknown for 19% of patients in the control group vs. 10% in the screening group 
(p<0.0001)(13). Lymph node status was missing for 5.0% of patients in the screening group 
and 7.3% of patients in the control group (p=0.0396)(13).  
It seems likely that Swedish trials have departed from the “ceteris paribus” principle by 
which an experiment evaluating the effect of one action must make sure that all other things 
remain equal and will not interfere with study results. 
In contrast, the Canadian trials that found no reduction in the risk of breast cancer death 
associated with mammography screening, adopted the typical parallel group randomized 
trial design. All enrolled women were volunteers who signed an informed consent form 
before randomization and received the same information and medical attention (10).  
A second reason for the persistent lower risk of breast cancer death for cancers found in the 
intervention and post-intervention periods could be biased attribution of causes of death. Of 
the 8 major breast screening trials, only the HIP and the Canadian trial implemented 
endpoint committees unaware of the screening status of deceased women. In left-to-nature 
trials, health professionals completing death certificates of being part of local endpoint 
committees may have known or guessed which women have been invited to screening but 
had no idea regarding women allocated to control groups. To circumvent this problem, the 
overview of 2002 used death certificates for cause of death assessment because the 
overview of 1993 found that causes reported on certificates correlated well with causes 
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established by an independent endpoint committee that had access to all medical and 
necropsy information (1). However, in the 2002 overview, there were nearly twice as many 
breast cancer deaths for the Malmö, Östergötland, Stockholm and Goteborg trials than in 
the 1993 overview (29) and it is unknown up to which point the reliability of death 
certificates was maintained over time. 
In conclusion, unconventional computation of the relative risk of breast cancer death 
impacted on the reported results of the Swedish trials on mammography screening. This led 
to an intrinsic bias in favor of screening. If calculations of relative risks had been carried out 
using similar methodological approaches to other cancer screening trials conducted in the 
more recent era, the Swedish trials would not have found a 20% reduction of breast cancer 
death due to mammography screening. This conclusion can be verified through a re-analysis 
of Swedish trial original data according to methods used in other cancer screening trials.  
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CAPTIONS 
 
Figure 1 – Design of randomized trials for the evaluation of cancer screening methods  
(R : screening round). Intervention periods are the continuous lines and the post-
intervention periods are the dashed lines. (a) Typical design; (b) design specific to Swedish 
trials on breast cancer screening. 
 
Box – Computation of relative risk (RR) of cancer death in randomized trials on cancer 
screening 
 
Table 1 - Data used for relative risks calculation in randomized trials on breast cancer 
screening 
Table 2 - Breast cancer deaths in the Swedish trials included in the 2002 overview 
Table 3 - Breast cancer deaths in Swedish mammography trials 
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Table 1 - Data used for relative risks calculation in randomized trials on breast cancer screening 
Trial 
No. 
First author, year 
of publication* 
Country, Study 
acronym 
Screening method 
(as compared to the 
control group) 
Follow-up period (years) 
Cause of 
death 
assessment 
Cancer-specific deaths used for 
calculation of the main relative risk 
associated with screening  
RR 95% CI Intervention  
period  
Post-
intervention 
period  
1 
Shapiro et al., 1997 
25
 
USA, Greater 
New-York Health 
Insurance Plan 
(HIP)  
MMS+BCE every 12 
months, 4 rounds  
5 13 0 
Cancer-specific deaths of cancers 
found during the intervention 
period 
0.77 NR 
2 Tabar et al., 2011 
26
 
Sweden, Two-
County trial † 
MMS, 2 to 4 rounds 7 22 
Local 
committee  
Cancer-specific deaths of cancers 
found during the intervention 
period plus, for the control group, 
incorporation of cancer-specific 
deaths of cancers found at first 
screening of this group 
0.69 0.56;0.85 
  id. id. id. id. id. 
Joint review 
commi;ee ‡ 
Cancer-specific deaths of cancers 
found during the intervention 
period plus, for the control group, 
incorporation of cancer-specific 
deaths of cancers found at first 
screening of this group 
0.73 0.59;0.89 
2 
Nyström et al., 
2002 # 
1
 
Sweden, 
Ostergotland § 
MMS, 2 to 4 rounds 7.7 9.7 
Death 
certificates 
Cancer-specific deaths of cancers 
found during the intervention 
period plus, for the control group, 
incorporation of cancer-specific 
deaths of cancers found at first 
screening of this group 
0.90 0.73;1.11 
3 
Nyström et al., 
2002 
1
 
Sweden, Malmö I 
MMS every 18-24 
months, 6 to 8 
rounds  
15 5 
Death 
certificates 
Cancer-specific deaths of cancers 
found during the intervention 
period plus, for the control group, 
incorporation of cancer-specific 
deaths of cancers found at first 
screening of this group 
0.82 0.67;1.00 
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Trial 
No. 
First author, year 
of publication* 
Country, Study 
acronym 
Screening method 
(as compared to the 
control group) 
Follow-up period (years) 
Cause of 
death 
assessment 
Cancer-specific deaths used for 
calculation of the main relative risk 
associated with screening  
RR 95% CI Intervention  
period  
Post-
intervention 
period  
4 
Nyström et al., 
2002 
1
 
Sweden, Malmö 
II 
MMS every 18-24 
months, 1 to 7 
rounds 
5.8 3.3 
Death 
certificates 
Cancer-specific deaths of cancers 
found during the intervention 
period plus, for the control group, 
incorporation of cancer-specific 
deaths of cancers found at first 
screening of this group 
0.64 0.39;1.06 
5 
Nyström et al., 
2002 
1
 
Sweden, 
Stockholm 
MMS every 24-28 
months, 2 rounds  
4.4 10.5 
Death 
certificates 
Cancer-specific deaths of cancers 
found during the intervention 
period plus, for the control group, 
incorporation of cancer-specific 
deaths of cancers found at first 
screening of this group 
0.91 0.65;1.27 
6 
Nyström et al., 
2002 
1
 
Sweden, 
Göteborg 
MMS, 3 to 5 rounds 
7 (women 
39-49) and 5 
(women 50-
59) 
7 (women 
39-49) and 9 
(women 50-
59) 
Death 
certificates 
Cancer-specific deaths of cancers 
found during the intervention 
period plus, for the control group, 
incorporation of cancer-specific 
deaths of cancers found at first 
screening of this group 
0.76 0.56;1.04 
7 
Miller et al., 2014 
22
 
Canada, NBSS I 
and II 
MMS every year, 4 
to 5 rounds 
5 20 
Committee 
unaware of 
screening 
status 
Cancer-specific deaths of cancers 
found during the intervention 
period 
1.05 0.85;1.30 
8 Moss et al., 2006 
27
 
England, Age 
trial 
MMS every 12 
months, 4 to 6 
rounds  
5 6 
Death 
certificates 
Cancer-specific deaths of cancers 
found during the intervention 
period 
0.83 0.66;1.04 
BC: breast cancer; BCE: breast physical examination; CG: control group; IG: intervention group; MMS: mammography screening; RR: relative risk. NBSS: National Breast 
Screening Study; TCT: Two-County trial (Dalarna [formerly Kopparberg] and Ostergötland counties). 
* The most recent publication reporting on main trial results is displayed in the Table. 
† This trial was done in the counHes of Dalarna (formerly Kopparberg) and Ostergötland. 
‡ The Joint Review Commi;ee included Two-County trial investigators (Holmberg et al., 2009 
28
) and has to be distinguished from the Independent Endpoint Committee set 
up by Swedish trial overviews (Nyström et al., 1993, 1995 
44,39
)  
§ The Ostergötland county trial was part of the Two-County trial, but results specific to the Ostergötland trial were published in Nyström et al., 2002. 
1
 
 
Page 41 of 51
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Journal of the Royal Society of Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Under Review
Table 2 - Breast cancer deaths in the Swedish trials included in the 2002 overview * 
 
Group 
No. women 
40-74 
included in 
trials † 
Person-years 
of follow-up 
(thousand) ‡ 
No. BC deaths related to: RR (95% CI) of BC death for BCs detected: 
  

BC found during 
the intervention 
period 
BC found during the 
post-intervention 
period 
BC found during 
the follow-up 
period 
During the 
intervention 
period 
(evaluation 
model) § 
During the 
post-
intervention 
period § 
During the 
follow-up 
period 
(follow-up 
model) § 
  As reported in the overview 
 
  
Screening  129750 1865 511 284 795 0.79 0.98 0.85 
Control  117260 1688 584 263 847 (0.70; 0.89) (0.83; 1.15) (0.77; 0.94) 
  
After re-allocation to the post-intervention period of 10% breast 
cancer deaths found at first screening of the control group #   
Screening  129750 1865 511 284 795 0.86 0.83 0.85 
Control  117260 1688 538 309 847 (0.76; 0.97) (0.71; 0.97) (0.77; 0.94) 
BC: breast cancer: PY: person-year; RR: relative risk. 
* Nyström et al., 2002 
1
; trials included in the overview are listed in Table 3. 
† Data from table 2 of Nyström et al., 2002 
1
 
‡ Data from table 4 of Nyström et al., 2002
 1
 
§ RR computed using No. of women 40-74 as denominator 
# See Table 3 for computation of BC deaths in the control group. 
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Table 3 - Breast cancer deaths in Swedish mammography trials 
 
Breast cancer deaths of: 
Screening 
group* 
Control 
group* 
BC deaths of BCs 
found at first 
screening of the 
control group (10% 
hypothesis†) 
Re-allocation of BC 
deaths found at 
first screening of 
the control group 
Corrected 
numbers of BC 
deaths in 
control groups 
BC found during intervention periods    
Malmö I  161 198 9 198 - 9 = 189 
Malmö II 29 33 2 33 - 2 = 31 
Ostergötland 177 190 19 190 - 19 = 171 
Stockholm 82 50 5 50 - 5 = 45 
Göteborg 62 113 11 113 - 11 = 102 
All five trials 511 584 46 584 - 46 = 538 
BC found during post-intervention periods‡ 284 263   263 + 46 = 309 
BC found during follow-up periods  795 847     847 
BC: breast cancer 
* From table 4 of Nystrom et al., 2002
1
 
† For Malmö I, the hypothesis was 4.5% and for Malmö II, the hypothesis was 7.5%. 
‡ Numbers of BCs in each trial during the post-intervention period were not provided. 
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Under Review
1 
Supplementary materials to:  
Statistical analyses in Swedish randomized trials on mammography screening and in other 
randomized trials on cancer screening: a systematic review 
Running title: Revisiting Swedish mammography trials 
Philippe Autier* 
1,2
; Mathieu Boniol 
1,2
; Michel Smans 
2
; Richard Sullivan 
3 
; Peter Boyle 
1,2 
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Etable 1 - Data used for relative risks calculation in randomized trials on cancer screening other than breast cancer screening 
Trial 
No. 
First author, year 
of publication 
reference
 
Country, 
study 
acronym (if 
provided) 
Target 
cancer 
Screening method 
(as compared to the 
control group) 
Follow-up period 
Cause of death 
assessment 
Cancer-specific deaths 
used for calculation of 
the main relative risk 
associated with 
screening 
Intervention 
period  
Post-
intervention 
period 
(years) 
1 
Shaukat et al., 
2013 (1) 
USA, MCCCS Colorectum 
FOBT (rehydrated) 
every year or every 
two years 
13 years 0 to 17 
Committee 
unaware of 
screening 
status 
Cancer-specific deaths 
of cancers found during 
the follow-up period 
2 
Scholefield et al., 
2012 (2) 
England Colorectum FOBT every two years 6.7 years 1 to 12.8 
One to 3 
investigators 
unaware of 
screening 
status 
Cancer-specific deaths 
of cancers found during 
the follow-up period 
3 
Jorgensen et al., 
2002 (3) 
Denmark Colorectum FOBT every two years 
10 to 13 
years 
0 
Committee 
unaware of 
screening 
status 
Cancer-specific deaths 
of cancers found during 
the follow-up period 
4 
Atkin et al., 2010 
(4) 
England Colorectum 
Once only flexible 
sigmoidoscopy 
Few weeks 
11.2 
(median) 
(i) Death 
certificates and 
(ii) cause of 
death assessed 
by 
independent 
coder unaware 
of screening 
status  
Cancer-specific deaths 
of cancers found during 
the follow-up period 
5 
Segnan et al., 
2011 (5) 
Italy Colorectum 
Once only flexible 
sigmoidoscopy 
Few weeks 
11.4 
(median) 
Committee 
unaware of 
Cancer-specific deaths 
of cancers found during 
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Trial 
No. 
First author, year 
of publication 
reference
 
Country, 
study 
acronym (if 
provided) 
Target 
cancer 
Screening method 
(as compared to the 
control group) 
Follow-up period 
Cause of death 
assessment 
Cancer-specific deaths 
used for calculation of 
the main relative risk 
associated with 
screening 
Intervention 
period  
Post-
intervention 
period 
(years) 
screening 
status 
the follow-up period 
6 
Schoen et al., 
2012 (6) 
USA, PLCO 
Cancer 
Screening 
Trial 
Colorectum 
Flexible 
sigmoidoscopy, two 
rounds 
3 or 5 years 6.9 or 8.9 
Committee 
unaware of 
screening 
status 
Cancer-specific deaths 
of cancers found during 
the follow-up period 
7 
Thiis-Evensen et 
al., 2013 (7) 
 Norway, TPS Colorectum 
One round of flexible 
sigmoidoscopy at 
year 1 and one round 
of colonoscopy or 
simoidoscopy in the 
intervention and in 
the control group at 
year 14 
14 years 12 
Death 
certificates 
Cancer-specific deaths 
of cancers found during 
the follow-up period 
8 
Holme et al., 2014 
(8) 
Norway Colorectum 
Once only flexible 
sigmoidoscopy with 
or without iFOBT 
Few weeks 
11.2 
(median) 
Death 
certificates 
Cancer-specific deaths 
of cancers found during 
the follow-up period 
9 
Sankaranarayanan 
et al., 2007 (9) 
India Cervix 
Once only visual 
inspection 
Few weeks 7 
Cancer registry 
staff unaware 
of screening 
status 
Cancer-specific deaths 
of cancers found during 
the follow-up period 
10 
Sankaranarayanan 
et al., 2009 (10) 
India Cervix 
Once only visual 
inspection or once 
only cytology, or once 
only HPV detection 
Few weeks 8 
Cancer registry 
staff unaware 
of screening 
status 
Cancer-specific deaths 
of cancers found during 
the follow-up period 
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Trial 
No. 
First author, year 
of publication 
reference
 
Country, 
study 
acronym (if 
provided) 
Target 
cancer 
Screening method 
(as compared to the 
control group) 
Follow-up period 
Cause of death 
assessment 
Cancer-specific deaths 
used for calculation of 
the main relative risk 
associated with 
screening 
Intervention 
period  
Post-
intervention 
period 
(years) 
11 
Andriole et al., 
2009 (11) 
USA, PLCO 
Cancer 
Screening 
Trial 
Prostate  
Digital rectal 
examination and 
serum PSA level 
every year 
6 1 to 4 
Committee 
unaware of 
screening 
status 
Cancer-specific deaths 
of cancers found during 
the follow-up period 
12 
Schröder et al., 
2014 (12) 
Europe, 
ERSPC 
Prostate  
Serum PSA level 
every 4 years 
8.8 to 13 
years 
(average) 
0 
Causes of 
death were 
evaluated in a 
blinded fashion 
and according 
to a standard 
algorithm 
Cancer-specific deaths 
of cancers found during 
the follow-up period 
13 
Oken et al., 2011
 
(13)
 
USA, PLCO 
Cancer 
Screening 
Trial 
Lung  
Chest X-ray every 
year 
3 years 10 
Committee 
unaware of 
screening 
status 
Cancer-specific deaths 
of cancers found during 
the follow-up period 
14 
Pastorino et al., 
2012 (14) 
Italy Lung  
Low-dose CT-Scan 
every, annual or 
biennial 
5 years 0 
Vital status of 
participants 
was traced 
blindly, 
without 
knowing the 
random 
allocation 
Cancer-specific deaths 
of cancers found during 
the follow-up period 
15 
Church et al., 
2013 (15) 
USA, NLST Lung  
Low-dose CT-Scan 
every year 
2 years 
4.5 
(median); 
Committee 
unaware of 
Cancer-specific deaths 
of cancers found during 
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Trial 
No. 
First author, year 
of publication 
reference
 
Country, 
study 
acronym (if 
provided) 
Target 
cancer 
Screening method 
(as compared to the 
control group) 
Follow-up period 
Cause of death 
assessment 
Cancer-specific deaths 
used for calculation of 
the main relative risk 
associated with 
screening 
Intervention 
period  
Post-
intervention 
period 
(years) 
7.4 
(maximum) 
screening 
status 
the follow-up period 
16 
Sankaranarayanan 
et al., 2013 (16) 
India, Kerala Mouth 
Three and 4 rounds 
of triennial visual 
inspection of the 
mouth  
10 0 to 5 
3 doctors 
unaware of 
screening 
status 
Cancer-specific deaths 
of cancers found during 
the follow-up period 
17 
Buys et al., 2011 
(17) 
USA, PLCO 
Cancer 
Screening 
Trial 
Ovary 
Annual serum CA 125 
for 6 years and 
annual TVU for 4 
years. 
6 6.4 (median) 
Committee 
unaware of 
screening 
status 
Cancer-specific deaths 
of cancers found during 
the follow-up period 
FOBT: fecal occult blood test based on guaiac reaction; iFOBT: immunological fecal occult blood test; RR: relative risk; TVU: transvaginal 
ultrasonography. 
ERSPC: European Randomized Study of Screening for Prostate Cancer; MCCCS: Minnesota Colon Cancer Control Study; NLST: National Lung 
Screening Trial ; PLCO: Prostate, Lung, Colorectal and Ovarian; TPS: Telemark Polyp Study. 
*The most recent publication reporting on main trial results is displayed in the Table. 
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